Latest News

The 15 years separating Generation X's oldest and youngest members are an important 15-year span for nearly everyone's finances.

While I'd rather have more control over my own money, I think RMDs have a silver lining.

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

The majority of investors see another year of positive returns ahead in 2026, with almost no one expecting a correction.

As part of the deal, AES shareholders will receive $15 per share in cash, representing a total equity value of $10.7 billion and an enterprise value of approximately $33.4 billion.

The stock's 27% surge in the past four trading days tells you a lot.

Analyst Joseph Moore reinstated Nvidia as the firm’s top choice in the sector, replacing Micron Technology.

The benchmark ETF is testing a critical technical breakdown. The move follows a sharp global selloff as escalating tensions in the Middle East sent oil prices soaring.

The oil giant has multiple upside catalysts.